Shared on 26 Sep 25
Fair value Decreased 2.62%ACADIA Pharmaceuticals’ consensus price target was revised downward to $29.32 as the Phase 3 failure of ACP-101 in Prader-Willi syndrome modestly reduced pipeline value, though the impact is seen as limited given low expectations and resilience in the core business. Analyst Commentary Bearish analysts cite the Phase 3 failure of ACP-101 in Prader-Willi syndrome (PWS), which missed its primary endpoint, leading to lowered price targets based on reduced near-term pipeline value.
Shared on 04 Sep 25
Fair value Increased 0.53%Analysts maintained their price target for ACADIA Pharmaceuticals at $29.95 as strong Daybue growth, favorable Nuplazid patent rulings, and strategic R&D focus offset near-term competitive and pipeline uncertainties. Analyst Commentary Bullish analysts are raising price targets citing strong Daybue growth in Q2, but note further acceleration is needed for material upside.
Shared on 23 Apr 25
Fair value Decreased 1.70%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 17 Apr 25
Fair value Increased 1.05%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
Fair value Decreased 11%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 19 Mar 25
Fair value Decreased 4.95%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 11 Mar 25
Fair value Decreased 4.04%AnalystConsensusTarget made no meaningful changes to valuation assumptions.